𝔖 Bobbio Scriptorium

✦ LIBER ✦

675 PUBLICATION Economic evaluation of capecitabine (X) vs. bolus 5-FU/LV as adjuvant chemotherapy for patients (pts) with Dukes' C colon cancer in an Italian hospital setting

Book ID: 118623252
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 146 KB
Volume: 3
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(05)80971-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN15 CAPECITABINE VS. BOLUS 5-FU/LV AS

PCN15 CAPECITABINE VS. BOLUS 5-FU/LV AS ADJUVANT THERAPY FOR PATIENTS WITH DUKES' C COLON CANCER: PHARMACOECONOMIC EVALUATION OF X-ACT TRIAL– DATA FROM CZECH PERSPECTIVE

✍ L Jiraskova; T Dolezal 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 69 KB

634 POSTER Post-study treatment does not

634 POSTER Post-study treatment does not influence outcome in the X-ACT phase III trial of capecitabine (X) vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with Dukes' C colon cancer

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 141 KB